While breast tumors with low levels of ER and PR expression (1-10%) are more likely to be luminal (46%) or HER-2-enriched (29%) by gene expression, the vast majority of ASCO/CAP-defined TNBCs (50-75%) are basal-like [10]. The gene discussed is ESR1; the disease is breast neoplasm.